TY - JOUR
T1 - Transfusion of Uncrossmatched Group O Erythrocyte-containing Products Does Not Interfere with Most ABO Typings
AU - Biomedical Excellence for Safer Transfusion Collaborative
AU - Yazer, Mark H.
AU - Spinella, Philip C.
AU - Doyle, Leilani
AU - Kaufman, Richard M.
AU - Dunn, Robyn
AU - Hess, John R.
AU - Filho, Luiz Amorim
AU - Fontaine, Magali
AU - Gathof, Birgit
AU - Jackson, Bryon
AU - Murphy, Michael F.
AU - Pasion, Jeremiah
AU - Raval, Jay S.
AU - Rosinski, Kristin
AU - Seheult, Jansen
AU - Shih, Andrew W.
AU - Sperry, Jason
AU - Staves, Julie
AU - Tuott, Erin E.
AU - Ziman, Alyssa
AU - Triulzi, Darrell J.
AU - McKenna, David
AU - Stroncek, David
AU - Fung, Mark
AU - Tinmouth, Alan
AU - Devine, Dana
AU - Cardigan, Rebecca
AU - Vassallo, Ralph
AU - Germain, Marc
AU - Reems, Jo Anna
AU - Garritsen, Henk
AU - Takanashi, Minoko
AU - Kaufman, Richard
AU - Stanworth, Simon
AU - Delaney, Meghan
AU - Cancelas, José
AU - van der Meer, Pieter
AU - Marks, Denese
AU - Cohn, Claudia
AU - Shaz, Beth
AU - Tiberghien, Pierre
AU - Goldman, Mindy
AU - Girdlestone, John
AU - Pati, Shibani
AU - Schäfer, Richard
AU - Schwartz, Joseph
AU - Dunbar, Nancy
AU - Yazer, Mark
AU - Pagano, Monica
AU - So-Osman, Cynthia
N1 - Publisher Copyright:
© 2019, the American Society of Anesthesiologists, Inc. All Rights Reserved.
PY - 2020/3/1
Y1 - 2020/3/1
N2 - Background: Group O erythrocytes and/or whole blood are used for urgent transfusions in patients of unknown blood type. This study investigated the impact of transfusing increasing numbers of uncrossmatched type O products on the recipient’s first in-hospital ABO type. Methods: This was a retrospective cohort study. Results of the first ABO type obtained in adult, non–type O recipients (i.e., types A, B, AB) after receiving at least one unit of uncrossmatched type O erythrocyte-containing product(s) for any bleeding etiology were analyzed along with the number of uncrossmatched type O erythrocyte-containing products administered in the prehospital and/or in hospital setting before the first type and screen sample was drawn. results: There were 10 institutions that contributed a total of 695 patient records. Among patients who received up to 10 uncrossmatched type O erythrocyte-containing products, the median A antigen agglutination strength in A and AB individuals on forward typing (i.e., testing the recipient’s erythrocytes for A and/or B antigens) was the maximum (4+), whereas the median B antigen agglutination strength among B and AB recipients of up to 10 units was 3 to 4+. The median agglutination strength on the reverse type (i.e., testing the recipient’s plasma for corresponding anti-A and -B antibodies) was very strong, between 3 and 4+, for recipients of up to 10 units of uncrossmatched erythrocyte-containing products. Overall, the ABO type of 665 of 695 (95.7%; 95% CI, 93.9 to 97.0%) of these patients could be accurately determined on the first type and screen sample obtained after transfusion of uncrossmatched type O erythrocyte-containing products. conclusions: The transfusion of smaller quantities of uncrossmatched type O erythrocyte-containing products, in particular up to 10 units, does not usually interfere with determining the recipient’s ABO type. The early collection of a type and screen sample is important.
AB - Background: Group O erythrocytes and/or whole blood are used for urgent transfusions in patients of unknown blood type. This study investigated the impact of transfusing increasing numbers of uncrossmatched type O products on the recipient’s first in-hospital ABO type. Methods: This was a retrospective cohort study. Results of the first ABO type obtained in adult, non–type O recipients (i.e., types A, B, AB) after receiving at least one unit of uncrossmatched type O erythrocyte-containing product(s) for any bleeding etiology were analyzed along with the number of uncrossmatched type O erythrocyte-containing products administered in the prehospital and/or in hospital setting before the first type and screen sample was drawn. results: There were 10 institutions that contributed a total of 695 patient records. Among patients who received up to 10 uncrossmatched type O erythrocyte-containing products, the median A antigen agglutination strength in A and AB individuals on forward typing (i.e., testing the recipient’s erythrocytes for A and/or B antigens) was the maximum (4+), whereas the median B antigen agglutination strength among B and AB recipients of up to 10 units was 3 to 4+. The median agglutination strength on the reverse type (i.e., testing the recipient’s plasma for corresponding anti-A and -B antibodies) was very strong, between 3 and 4+, for recipients of up to 10 units of uncrossmatched erythrocyte-containing products. Overall, the ABO type of 665 of 695 (95.7%; 95% CI, 93.9 to 97.0%) of these patients could be accurately determined on the first type and screen sample obtained after transfusion of uncrossmatched type O erythrocyte-containing products. conclusions: The transfusion of smaller quantities of uncrossmatched type O erythrocyte-containing products, in particular up to 10 units, does not usually interfere with determining the recipient’s ABO type. The early collection of a type and screen sample is important.
UR - http://www.scopus.com/inward/record.url?scp=85079250751&partnerID=8YFLogxK
U2 - 10.1097/ALN.0000000000003069
DO - 10.1097/ALN.0000000000003069
M3 - Article
C2 - 31789634
AN - SCOPUS:85079250751
SN - 0003-3022
VL - 132
SP - 525
EP - 534
JO - Anesthesiology
JF - Anesthesiology
IS - 3
ER -